Partner Nathaniel Lacktman was quoted in a Bloomberg BNA Health Law Reporter article, “Online Eye-Test Company Sues State, Says Licensing Law Violates S.C. Constitution,” on November 3, 2016. The article discussed telemedicine provider Opternative’s challenge against a South Carolina law that forbids the use of automated eye tests for renewing corrective lens prescriptions.
Lacktman said the suit is another example in a wave of telehealth providers pushing back against restrictive state laws and rules. He was quoted saying, “I respect the efforts of telehealth companies like Opternative to continue to advocate for patient’s rights to enjoy convenient, accessible healthcare. Ideally, state laws and regulations should strike the right balance between ensuring patient safety and promoting innovation and efficiencies in the way healthcare is delivered.”
Lacktman said the suit is another example in a wave of telehealth providers pushing back against restrictive state laws and rules. He was quoted saying, “I respect the efforts of telehealth companies like Opternative to continue to advocate for patient’s rights to enjoy convenient, accessible healthcare. Ideally, state laws and regulations should strike the right balance between ensuring patient safety and promoting innovation and efficiencies in the way healthcare is delivered.”
People
Related News
25 July 2024
In the News
Donald Schroeder on Groff – ‘Supreme Court decision is inviting a more fact-based analysis’
Foley & Lardner LLP partner Donald Schroeder assessed the impact of the U.S. Supreme Court’s 2023 decision in a religious accommodation case as it returns to the district court in the Law360 article, “A Year After High Court Spotlight, Groff Case Still A Bellwether.”
24 July 2024
In the News
Louis Lehot Featured in Q&A on How Startups Can Prepare for IPO
Foley & Lardner LLP partner Louis Lehot features in the Q&A, "How startups can get in top shape for an IPO, according to Silicon Valley lawyer Louis Lehot," part of Business Insider's Road to IPO' series.
24 July 2024
In the News
Courtenay Brinckerhoff on Patent Cap in Drug Pricing – ‘Hard to predict if this will make a difference’
Foley & Lardner LLP partner Courtenay Brinckerhoff discussed a recent bill passed in the U.S. Senate aimed at lowering drug prices by limiting the number of patents that can be asserted in cases over biosimilars in the Law360 article, “Patent Cap In Drug Pricing Bill Seen As Having Muted Effect.”